HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS

Provided herein are Heteroaryl Compounds having the following structure: (I) wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological condit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: JASON SIMON PARNES, PATRICK WILLIAM PAPA, SOPHIE PERRIN-NINKOVIC, DEHUA HUANG, MARIA MERCEDES MEDEROS DELGADO, LIDA RADNIA TEHRANI, BRANDEN G. LEE, DEBORAH SUE MORTENSEN, GARRICK K. PACKARD, RONALD J. ALBERS, JOHN JOSEPH SAPIENZA, ROY LEONARD HARRIS III, GRAZIELLA ISABEL SHEVLIN, KIMBERLY LYN SCHWARZ
Format: Patent
Sprache:eng ; spa
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator JASON SIMON PARNES
PATRICK WILLIAM PAPA
SOPHIE PERRIN-NINKOVIC
DEHUA HUANG
MARIA MERCEDES MEDEROS DELGADO
LIDA RADNIA TEHRANI
BRANDEN G. LEE
DEBORAH SUE MORTENSEN
GARRICK K. PACKARD
RONALD J. ALBERS
JOHN JOSEPH SAPIENZA
ROY LEONARD HARRIS III
GRAZIELLA ISABEL SHEVLIN
KIMBERLY LYN SCHWARZ
description Provided herein are Heteroaryl Compounds having the following structure: (I) wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof. Se proporcionan aquí los compuestos heterocíclicos que tienen la siguiente estructura: (I) en donde R1, R2, L, X, Y, Z, Q, A y B son como se definen aquí, las composiciones que comprenden una cantidad efectiva de un compuesto de heteroarilo y métodos para el tratamiento o prevención del cáncer, condiciones inflamatorias, condiciones inmunológicas, condiciones metabólicas y condiciones tratables o prevenibles por inhibición de una vía o trayectoria de la cinasa, que comprende la administración de una cantidad efectiva de un compuesto de heteroarilo a un paciente en necesidad del mismo.(ver fórmula (I)).
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_MX337906B</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>MX337906B</sourcerecordid><originalsourceid>FETCH-epo_espacenet_MX337906B3</originalsourceid><addsrcrecordid>eNrjZAjzcA1xDfJ3DIr0UXD29w3wD_VzCdaBMIM9Qzz9_YIVQjxcg1z93XQUHP1cQBzPIIXQYFcFx2CFgCD_EFdPPwVvTz9HoIinn4enk2eIf1AwDwNrWmJOcSovlOZmkHNzDXH20E0tyI9PLS5ITE7NSy2J940wNja3NDBzMiaoAACf2y_j</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS</title><source>esp@cenet</source><creator>JASON SIMON PARNES ; PATRICK WILLIAM PAPA ; SOPHIE PERRIN-NINKOVIC ; DEHUA HUANG ; MARIA MERCEDES MEDEROS DELGADO ; LIDA RADNIA TEHRANI ; BRANDEN G. LEE ; DEBORAH SUE MORTENSEN ; GARRICK K. PACKARD ; RONALD J. ALBERS ; JOHN JOSEPH SAPIENZA ; ROY LEONARD HARRIS III ; GRAZIELLA ISABEL SHEVLIN ; KIMBERLY LYN SCHWARZ</creator><creatorcontrib>JASON SIMON PARNES ; PATRICK WILLIAM PAPA ; SOPHIE PERRIN-NINKOVIC ; DEHUA HUANG ; MARIA MERCEDES MEDEROS DELGADO ; LIDA RADNIA TEHRANI ; BRANDEN G. LEE ; DEBORAH SUE MORTENSEN ; GARRICK K. PACKARD ; RONALD J. ALBERS ; JOHN JOSEPH SAPIENZA ; ROY LEONARD HARRIS III ; GRAZIELLA ISABEL SHEVLIN ; KIMBERLY LYN SCHWARZ</creatorcontrib><description>Provided herein are Heteroaryl Compounds having the following structure: (I) wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof. Se proporcionan aquí los compuestos heterocíclicos que tienen la siguiente estructura: (I) en donde R1, R2, L, X, Y, Z, Q, A y B son como se definen aquí, las composiciones que comprenden una cantidad efectiva de un compuesto de heteroarilo y métodos para el tratamiento o prevención del cáncer, condiciones inflamatorias, condiciones inmunológicas, condiciones metabólicas y condiciones tratables o prevenibles por inhibición de una vía o trayectoria de la cinasa, que comprende la administración de una cantidad efectiva de un compuesto de heteroarilo a un paciente en necesidad del mismo.(ver fórmula (I)).</description><language>eng ; spa</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; METALLURGY ; ORGANIC CHEMISTRY</subject><creationdate>2016</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20160328&amp;DB=EPODOC&amp;CC=MX&amp;NR=337906B$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20160328&amp;DB=EPODOC&amp;CC=MX&amp;NR=337906B$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>JASON SIMON PARNES</creatorcontrib><creatorcontrib>PATRICK WILLIAM PAPA</creatorcontrib><creatorcontrib>SOPHIE PERRIN-NINKOVIC</creatorcontrib><creatorcontrib>DEHUA HUANG</creatorcontrib><creatorcontrib>MARIA MERCEDES MEDEROS DELGADO</creatorcontrib><creatorcontrib>LIDA RADNIA TEHRANI</creatorcontrib><creatorcontrib>BRANDEN G. LEE</creatorcontrib><creatorcontrib>DEBORAH SUE MORTENSEN</creatorcontrib><creatorcontrib>GARRICK K. PACKARD</creatorcontrib><creatorcontrib>RONALD J. ALBERS</creatorcontrib><creatorcontrib>JOHN JOSEPH SAPIENZA</creatorcontrib><creatorcontrib>ROY LEONARD HARRIS III</creatorcontrib><creatorcontrib>GRAZIELLA ISABEL SHEVLIN</creatorcontrib><creatorcontrib>KIMBERLY LYN SCHWARZ</creatorcontrib><title>HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS</title><description>Provided herein are Heteroaryl Compounds having the following structure: (I) wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof. Se proporcionan aquí los compuestos heterocíclicos que tienen la siguiente estructura: (I) en donde R1, R2, L, X, Y, Z, Q, A y B son como se definen aquí, las composiciones que comprenden una cantidad efectiva de un compuesto de heteroarilo y métodos para el tratamiento o prevención del cáncer, condiciones inflamatorias, condiciones inmunológicas, condiciones metabólicas y condiciones tratables o prevenibles por inhibición de una vía o trayectoria de la cinasa, que comprende la administración de una cantidad efectiva de un compuesto de heteroarilo a un paciente en necesidad del mismo.(ver fórmula (I)).</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2016</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZAjzcA1xDfJ3DIr0UXD29w3wD_VzCdaBMIM9Qzz9_YIVQjxcg1z93XQUHP1cQBzPIIXQYFcFx2CFgCD_EFdPPwVvTz9HoIinn4enk2eIf1AwDwNrWmJOcSovlOZmkHNzDXH20E0tyI9PLS5ITE7NSy2J940wNja3NDBzMiaoAACf2y_j</recordid><startdate>20160328</startdate><enddate>20160328</enddate><creator>JASON SIMON PARNES</creator><creator>PATRICK WILLIAM PAPA</creator><creator>SOPHIE PERRIN-NINKOVIC</creator><creator>DEHUA HUANG</creator><creator>MARIA MERCEDES MEDEROS DELGADO</creator><creator>LIDA RADNIA TEHRANI</creator><creator>BRANDEN G. LEE</creator><creator>DEBORAH SUE MORTENSEN</creator><creator>GARRICK K. PACKARD</creator><creator>RONALD J. ALBERS</creator><creator>JOHN JOSEPH SAPIENZA</creator><creator>ROY LEONARD HARRIS III</creator><creator>GRAZIELLA ISABEL SHEVLIN</creator><creator>KIMBERLY LYN SCHWARZ</creator><scope>EVB</scope></search><sort><creationdate>20160328</creationdate><title>HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS</title><author>JASON SIMON PARNES ; PATRICK WILLIAM PAPA ; SOPHIE PERRIN-NINKOVIC ; DEHUA HUANG ; MARIA MERCEDES MEDEROS DELGADO ; LIDA RADNIA TEHRANI ; BRANDEN G. LEE ; DEBORAH SUE MORTENSEN ; GARRICK K. PACKARD ; RONALD J. ALBERS ; JOHN JOSEPH SAPIENZA ; ROY LEONARD HARRIS III ; GRAZIELLA ISABEL SHEVLIN ; KIMBERLY LYN SCHWARZ</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_MX337906B3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; spa</language><creationdate>2016</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><toplevel>online_resources</toplevel><creatorcontrib>JASON SIMON PARNES</creatorcontrib><creatorcontrib>PATRICK WILLIAM PAPA</creatorcontrib><creatorcontrib>SOPHIE PERRIN-NINKOVIC</creatorcontrib><creatorcontrib>DEHUA HUANG</creatorcontrib><creatorcontrib>MARIA MERCEDES MEDEROS DELGADO</creatorcontrib><creatorcontrib>LIDA RADNIA TEHRANI</creatorcontrib><creatorcontrib>BRANDEN G. LEE</creatorcontrib><creatorcontrib>DEBORAH SUE MORTENSEN</creatorcontrib><creatorcontrib>GARRICK K. PACKARD</creatorcontrib><creatorcontrib>RONALD J. ALBERS</creatorcontrib><creatorcontrib>JOHN JOSEPH SAPIENZA</creatorcontrib><creatorcontrib>ROY LEONARD HARRIS III</creatorcontrib><creatorcontrib>GRAZIELLA ISABEL SHEVLIN</creatorcontrib><creatorcontrib>KIMBERLY LYN SCHWARZ</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>JASON SIMON PARNES</au><au>PATRICK WILLIAM PAPA</au><au>SOPHIE PERRIN-NINKOVIC</au><au>DEHUA HUANG</au><au>MARIA MERCEDES MEDEROS DELGADO</au><au>LIDA RADNIA TEHRANI</au><au>BRANDEN G. LEE</au><au>DEBORAH SUE MORTENSEN</au><au>GARRICK K. PACKARD</au><au>RONALD J. ALBERS</au><au>JOHN JOSEPH SAPIENZA</au><au>ROY LEONARD HARRIS III</au><au>GRAZIELLA ISABEL SHEVLIN</au><au>KIMBERLY LYN SCHWARZ</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS</title><date>2016-03-28</date><risdate>2016</risdate><abstract>Provided herein are Heteroaryl Compounds having the following structure: (I) wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof. Se proporcionan aquí los compuestos heterocíclicos que tienen la siguiente estructura: (I) en donde R1, R2, L, X, Y, Z, Q, A y B son como se definen aquí, las composiciones que comprenden una cantidad efectiva de un compuesto de heteroarilo y métodos para el tratamiento o prevención del cáncer, condiciones inflamatorias, condiciones inmunológicas, condiciones metabólicas y condiciones tratables o prevenibles por inhibición de una vía o trayectoria de la cinasa, que comprende la administración de una cantidad efectiva de un compuesto de heteroarilo a un paciente en necesidad del mismo.(ver fórmula (I)).</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; spa
recordid cdi_epo_espacenet_MX337906B
source esp@cenet
subjects CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
title HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T03%3A29%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=JASON%20SIMON%20PARNES&rft.date=2016-03-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EMX337906B%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true